Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Syndax Pharmaceuticals

Why Is Syndax Stock Down Today?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) are trading lower Friday following approval of one of its treatments from the U.S.’s Food and Drug Administration.

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.

2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

The recent advancements in their pipelines imply high growth potential in the coming years.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022

Syndax Pharmaceuticals's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted a total of $126.58 million in sales, a 922.84% increase since Q3.

Recap: Syndax Pharmaceuticals Q4 Earnings

Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Organisations

Palantir Technologies

B of A Securities

Rivian Automotive

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play